Get started
BIOMARIN PHARMACEUTICAL COM STK USD0.001BIOMARIN PHARMACEUTICAL COM STK USD0.001BIOMARIN PHARMACEUTICAL COM STK USD0.001

BIOMARIN PHARMACEUTICAL COM STK USD0.001

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

0HNC chart


Full chart

0HNC upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪11.35 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
26.8
Basic EPS (TTM)
2.2 USD
Net income (FY)
‪426.86 M‬ USD
Revenue (FY)
‪2.84 B‬ USD
Shares float
‪189.25 M‬
Beta (1Y)
0.42

Employees


Employees (FY)
‪3.04 K‬
Change (1Y)
−361 −10.61%
Revenue / Employee (1Y)
‪933.95 K‬ USD
Net income / Employee (1Y)
‪140.41 K‬ USD

About BioMarin Pharmaceutical Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Alexander Hardy
Website
biomarin.com
Headquarters
San Rafael
Founded
1997
FIGI
BBG00JRQRV85
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

0HNC news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

0HNC highest yielding bonds


BMRN5187965
BioMarin Pharmaceutical Inc. 1.25% 15-MAY-2027
Yield to maturity
4.74%
Maturity date
May 15, 2027

See all 0HNC bonds 

Sparks


Curated watchlists where 0HNC is featured.

See all sparks 


Check out other big names from the same industry as 0HNC.

Frequently Asked Questions


The current price of 0HNC is 59.2 USD — it has increased by 0.68% in the past 24 hours. Watch BIOMARIN PHARMACEUTICAL COM STK USD0.001 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange BIOMARIN PHARMACEUTICAL COM STK USD0.001 stocks are traded under the ticker 0HNC.
0HNC stock has risen by 2.94% compared to the previous week, the month change is a −16.53% fall, over the last year BIOMARIN PHARMACEUTICAL COM STK USD0.001 has showed a −34.80% decrease.
We've gathered analysts' opinions on BIOMARIN PHARMACEUTICAL COM STK USD0.001 future price: according to them, 0HNC price has a max estimate of 126.00 USD and a min estimate of 65.00 USD. Watch 0HNC chart and read a more detailed BIOMARIN PHARMACEUTICAL COM STK USD0.001 stock forecast: see what analysts think of BIOMARIN PHARMACEUTICAL COM STK USD0.001 and suggest that you do with its stocks.
0HNC reached its all-time high on Jul 22, 2020 with the price of 126.8 USD, and its all-time low was 53.6 USD and was reached on Apr 9, 2025. View more price dynamics on 0HNC chart.
See other stocks reaching their highest and lowest prices.
0HNC stock is 2.24% volatile and has beta coefficient of 0.42. Track BIOMARIN PHARMACEUTICAL COM STK USD0.001 stock price on the chart and check out the list of the most volatile stocks — is BIOMARIN PHARMACEUTICAL COM STK USD0.001 there?
Today BIOMARIN PHARMACEUTICAL COM STK USD0.001 has the market capitalization of ‪11.35 B‬, it has increased by 0.99% over the last week.
Yes, you can track BIOMARIN PHARMACEUTICAL COM STK USD0.001 financials in yearly and quarterly reports right on TradingView.
BIOMARIN PHARMACEUTICAL COM STK USD0.001 is going to release the next earnings report on May 1, 2025. Keep track of upcoming events with our Earnings Calendar.
0HNC earnings for the last quarter are 0.64 USD per share, whereas the estimation was 0.53 USD resulting in a 19.84% surprise. The estimated earnings for the next quarter are 0.69 USD per share. See more details about BIOMARIN PHARMACEUTICAL COM STK USD0.001 earnings.
BIOMARIN PHARMACEUTICAL COM STK USD0.001 revenue for the last quarter amounts to ‪747.00 M‬ USD, despite the estimated figure of ‪712.30 M‬ USD. In the next quarter, revenue is expected to reach ‪740.10 M‬ USD.
0HNC net income for the last quarter is ‪124.94 M‬ USD, while the quarter before that showed ‪106.08 M‬ USD of net income which accounts for 17.78% change. Track more BIOMARIN PHARMACEUTICAL COM STK USD0.001 financial stats to get the full picture.
No, 0HNC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 20, 2025, the company has ‪3.04 K‬ employees. See our rating of the largest employees — is BIOMARIN PHARMACEUTICAL COM STK USD0.001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOMARIN PHARMACEUTICAL COM STK USD0.001 EBITDA is ‪571.64 M‬ USD, and current EBITDA margin is 22.06%. See more stats in BIOMARIN PHARMACEUTICAL COM STK USD0.001 financial statements.
Like other stocks, 0HNC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOMARIN PHARMACEUTICAL COM STK USD0.001 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOMARIN PHARMACEUTICAL COM STK USD0.001 technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOMARIN PHARMACEUTICAL COM STK USD0.001 stock shows the strong sell signal. See more of BIOMARIN PHARMACEUTICAL COM STK USD0.001 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.